GLP-1 receptor agonist use was associated with higher and incidence than DPP-4 or SGLT-2 inhibitors in adults with diabetes.
Evidence
This retrospective target trial emulation used TriNetX electronic health records to compare 95,190 GLP-1RA versus DPP-4i pairs and 82,789 GLP-1RA versus SGLT-2i pairs of adults with diabetes on biguanides.
Caveat
Because the study used de-identified EHR data, the elevated hazard ratios remain observational associations that may reflect residual confounding or infection ascertainment differences.
Simplified
BACKGROUND: (GLP-1RA) are effective for glycemic control and cardiometabolic outcomes, but their infectious safety, particularly regarding (HSV) and (HZ), is underexplored. This study evaluated the association between GLP-1RA therapy and risks of HSV and HZ infections in patients with DM, compared to sodium-glucose co-transporter-2 inhibitors (SGLT-2i) and dipeptidyl peptidase-4 inhibitors (DPP-4i).
METHODS: We conducted a retrospective cohort analysis using target trial emulation principles on de-identified electronic health records from the TriNetX U.S. Network (2015-2022). Adults aged ≥ 18 years with diabetes prescribed biguanides were included. New users of GLP-1RA were compared to DPP-4i users in the first cohort and SGLT-2i users in the second cohort. Primary outcomes were HSV and HZ incidence, analyzed with Kaplan-Meier curves and Cox proportional hazards models.
RESULTS: Among 95,190 GLP-1RA vs. DPP-4i pairs and 82,789 GLP-1RA vs. SGLT-2i pairs, GLP-1RA therapy was associated with higher risks of HSV (HR = 1.387, 95% CI = 1.249-1.539) and HZ (HR = 1.294, 95% CI = 1.203-1.392) compared to DPP-4i and HSV (HR = 1.277, 95% CI = 1.132-1.442) and HZ (HR = 1.18, 95% CI = 1.085-1.284) compared to SGLT-2i. Younger patients (18-50 years) on GLP-1RAs had elevated risks for HSV (HR = 1.632) and HZ (HR = 1.553). Female GLP-1RA users showed increased HSV risk (HR = 1.51), and poorly controlled patients (HbA1c ≥ 7%) had higher HSV risks (HR = 1.195). Herpes zoster vaccination mitigated these risks.
CONCLUSIONS: GLP-1RA use is associated with an increased risk of HSV and HZ infections compared with SGLT-2i or a DPP-4i use, especially in younger, female, and poorly controlled T2DM patients. Vaccination against herpes zoster is essential in mitigating these risks.
Key numbers
1.387
Increase in Risk
Hazard ratio for infection comparing GLP-1RA to DPP-4i.
1.294
Increase in Risk
Hazard ratio for infection comparing GLP-1RA to DPP-4i.
1.632
Higher Risk in Younger Patients
Hazard ratio for infection in younger patients (18-50 years) on GLP-1RA.
Full Text
We can’t show the full text here under this license.
GLP-1 Therapies